会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Quinoline type mevalonolactones useful for treating hyperlipidemia,
hyperlipoproteinemia or atherosclerosis
    • 可用于治疗高脂血症,高脂蛋白血症或动脉粥样硬化的喹啉型甲羟戊酸
    • US5185328A
    • 1993-02-09
    • US483829
    • 1990-02-23
    • Yoshihiro FukikawaMikio SuzukiHiroshi IwasakiMitsuaki SakashitaMasaki Kitahara
    • Yoshihiro FukikawaMikio SuzukiHiroshi IwasakiMitsuaki SakashitaMasaki Kitahara
    • C07D215/14C07D215/18C07D215/20C07D405/06
    • C07D405/06C07D215/14C07D215/18C07D215/20
    • A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are independently hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, sec-butoxy, R.sup.7 R.sup.8 N-- (wherein R.sup.7 and R.sup.8 are independently hydrogen or C.sub.1-3 alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or --O(CH.sub.2).sub.l OR.sup.19 (wherein R.sup.19 is hydrogen or C.sub.1-3 alkyl, and l is 1,2 or 3); or when located at the ortho position to each other, R.sup.1 and R.sup.2, or R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH--; or when located at the ortho position to each other, R.sup.1 and R.sup.2 together form --OC(R.sup.15 l) (R.sup.16)O-- (wherein R.sup.15 and R.sup.16 are independently hydrogen or C.sub.1-3 alkyl); Y is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --CH.dbd.CH-- or -- CH.dbd.CH--CH.sub.2 --; and Z is --Q--CH.sub.2 WCH.sub.2 --CO.sub.2 R.sup.12, ##STR2## (wherein Q is --C(O)--, --C(OR.sup.13).sub.2 -- or --CH(OH)--; W is --C(O)--, --C(OR.sup.13).sub.2 -- or --C(R.sup.11) (OH)--; R.sup.11 is hydrogen atom or C.sub.1-3 alkyl; R.sup.12 is hydrogen or R.sup.14 (wherein R.sup.14 is physiologically hydrolyzable alkyl or M (wherein M is NH.sub.4, sodium, potassium, 1/2 calcium or a hydrate of lower alkyl amine, di-lower alkyl amine or tri-lower alkyl amine)); two R.sup.13 are independently primary or secondary C.sub.1-6 alkyl; or two R.sup.13 together form --(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.3 ; R.sup.17 and R.sup.18 are independently hydrogen or C.sub.1-3 alkyl; and R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.2-3 alkenyl, C.sub.3-6 cycloalkyl, ##STR3## wherein R.sup.9 is a hydrogen atom, C.sub.1-4 alkyl, C.sub.1-3 alkoxy, fluoro, chloro, bromo or trifluoromethyl), phenyl--(CH.sub.2).sub.m -- (wherein m is 1,2 or 3), --(CH.sub.2).sub.n CH(CH.sub.3)--phenyl or phenyl--(CH.sub.2).sub.n CH(CH.sub.3)-- (wherein n is 0,1 or 2).
    • 下式的化合物:其中R 1,R 2,R 3,R 4和R 6独立地是氢,C 1-6烷基,C 1-6环烷基,C 1-3烷氧基,正丁氧基,异丁氧基,仲丁氧基, 丁氧基,R7R8N-(其中R7和R8独立地是氢或C1-3烷基),三氟甲基,三氟甲氧基,二氟甲氧基,氟,氯,溴,苯基,苯氧基,苄氧基,羟基,三甲基甲硅烷氧基,二苯基叔丁基甲硅烷氧基,羟甲基或 - O(CH 2)lOR 19(其中R 19是氢或C 1-3烷基,且l是1,2或3); 或当位于彼此的邻位时,R1和R2,或R3和R4一起形成-CH = CH-CH = CH-; 或当位于彼此的邻位时,R1和R2一起形成-OC(R151)(R16)O-(其中R15和R16独立地为氢或C1-3烷基); Y是-CH 2 - , - CH 2 CH 2 - , - CH = CH - , - CH 2 -CH = CH-或-CH = CH-CH 2 - ; (其中Q为-C(O) - , - C(OR 13)2 - 或-CH(OH) - ); W为-C(O) - (CH 2) ,-C(OR 13)2 - 或-C(R 11)(OH) - ; R 11为氢原子或C 1-3烷基; R 12为氢或R 14(其中R 14为生理上可水解的烷基或M(其中M为NH 4,钠 ,二价低级烷基胺或三低级烷基胺的水合物));两个R 13独立地为伯或仲C 1-6烷基;或两个R 13一起形成 - (CH 2) 2-或 - (CH 2)3; R 17和R 18独立地是氢或C 1-3烷基; R 5是氢,C 1-6烷基,C 2-3烯基,C 3-6环烷基,其中R 9是氢原子 ,C 1-4烷基,C 1-3烷氧基,氟,氯,溴或三氟甲基),苯基 - (CH 2)m - (其中m为1,2或3), - (CH 2)n CH(CH 3) - (CH 2)n CH(CH 3) - (其中n为0,1或2)。